Screen Shot 2015-05-01 at 9.05.41 AM.png
axon_degeneration_bw.jpg
Denali_SF.jpeg
Investers.jpg
Screen Shot 2015-05-01 at 9.05.41 AM.png

DEFEAT DEGENERATION


Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.

SCROLL DOWN

DEFEAT DEGENERATION


Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.

 
 
 

Denali was founded by scientists, drug developers and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for patients suffering from neurodegenerative disease.

 

More about us.

 
 
axon_degeneration_bw.jpg

THE TIME IS RIGHT


Recent groundbreaking scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases offer an unprecedented opportunity for the discovery and development of effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases.

 

SCROLL DOWN

THE TIME IS RIGHT


Recent groundbreaking scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases offer an unprecedented opportunity for the discovery and development of effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases.

 

 

PATHWAY POTENTIAL

 

Advances in the genetics, pathology and cell biology underlying chronic neurodegenerative disease have identified pathways that trigger neurodegeneration and contribute to disease onset and progression. Denali is applying deep scientific and drug development expertise to fully harvest the potential of these pathways in order to discover effective molecular therapeutics.

 

Discover our science.

 
Investers.jpg

FOUNDING INVESTORS


Founding investors in Denali’s Series A financing include ARCH Venture Partners, F-Prime Biosciences, Flagship Ventures as well as the Alaska Permanent Fund. Baillie Gifford, a UK based mutual fund, led Denali’s Series B financing and was joined by several other major institutional investors, sovereign wealth funds and private investors.

SCROLL DOWN

FOUNDING INVESTORS


Founding investors in Denali’s Series A financing include ARCH Venture Partners, F-Prime Biosciences, Flagship Ventures as well as the Alaska Permanent Fund. Baillie Gifford, a UK based mutual fund, led Denali’s Series B financing and was joined by several other major institutional investors, sovereign wealth funds and private investors.